On May 26, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. The event will take place May 29 – June 3, 2026 in Chicago, Illinois.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This year’s ASCO (Free ASCO Whitepaper) Annual Meeting marks a significant milestone for Tempus, as we are presenting our largest collection of accepted research to date, further underscoring the critical role that multimodal data and AI-driven insights play in advancing precision medicine across oncology," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "The breadth of our findings demonstrates the tangible impact of these tools in transforming complex real-world data into actionable evidence, helping more patients benefit from the next generation of innovative therapies."
Research highlights include:
Saturday, May 30, 2026
9:00am – 12:00pm CT
Impact of AI-augmented histopathology review on next-generation sequencing (NGS) success
Poster Board: 536; Abstract Number: 1618
AI-driven RNA-based homologous recombination deficiency algorithm to predict first-line platinum response in metastatic pancreatic cancer.
Poster Board: 193; Abstract Number: 4210
1:30 pm – 4:30 pm CT
ESR1 mutation longitudinal dynamics in RWD cohort of HR+/HER2- metastatic breast cancer patients treated with standard of care hormonal therapy
Poster Board: 199; Abstract Number: 3062
First-line lenvatinib versus dabrafenib plus trametinib (D+T) in BRAF-mutated differentiated thyroid cancer (DTC): Insights from real-world data.
Poster Board: 509; Abstract Number: 6052
Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors
Poster Board: 219; Abstract Number: 3082
Sunday, May 31, 2026
9:00am – 12:00pm CT
Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve early-stage NSCLC biomarker testing
Poster Board: 518; Abstract Number: 8044
Monday, June 1, 2026
9:00 am – 12:00 pm CT
Whole genome sequencing to identify novel, clinically relevant findings missed by standard of care for patients with myelodysplastic syndrome
Poster Board: 363; Abstract Number: 6570
1:30 pm – 4:30 pm CT
GEMINI-BREAST: Evaluating minimal residual disease (MRD) through longitudinal circulating tumor DNA (ctDNA) profiling in breast malignancies
Poster Board: 130b; Abstract Number: TPS649
Explore the full scope of Tempus-authored research and discover how the company is advancing precision medicine at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting here.
(Press release, Tempus, MAY 26, 2026, View Source [SID1234666073])